Table 2. 5-year budgetary impact concerning the treatment of SHPT on CKD for the dialysis population using vitamin-D analogues with paricalcitol use expansion (SABEIS scenarios).
| Year | Eligible population | Budgetary impact with oral calcitriol * (Base scenario) | Diffusion rate for paricalcitol | Budgetary impact with paricalcitol ** and calcitriol * (proposed scenario) | Incremental budgetary impact with paricalcitol |
|---|---|---|---|---|---|
| 2021 | 27.363 | R$ 86.938.486,13 | 15% | R$ 88.538.688,40 | R$ 1.600.202,28 |
| 2022 | 27.135 | R$ 91.286.039,52 | 16% | R$ 94.754.518,27 | R$ 3.468.478,85 |
| 2023 | 25.140 | R$ 95.850.341,50 | 18% | R$ 103.247.579,23 | R$ 7.397.237,73 |
| 2024 | 17.598 | R$ 100.642.829,98 | 23% | R$ 118.267.679,09 | R$ 17.624.850,11 |
| 2025 | 18.478 | R$ 105.674.942,88 | 23% | R$ 124.181.029,44 | R$18.506.086,56 |
| Total in 5 years | R$ 480.392.640,01 | - | R$ 528.989.495,51 | R$ 48.596.855,50 |
*
Annual cost of treatment with oral calcitriol per patient = R$ 1.360,32;
**
Annual cost of treatment with paricalcitol, per patient = R$ 2.574,00. DAF: pharmacy assistance department; CKD: chronic kidney disease; SHPT: second hyperparathyroidism.